Effectiveness of JN.1 monovalent COVID-19 vaccination in EU/EEA countries between October 2024 and January 2025: a VEBIS electronic health record network study.

Saved in:
Bibliographic Details
Title: Effectiveness of JN.1 monovalent COVID-19 vaccination in EU/EEA countries between October 2024 and January 2025: a VEBIS electronic health record network study.
Authors: Humphreys J; Epiconcept, Paris, France. Electronic address: j.humphreys@epiconcept.fr., Blake A; Epiconcept, Paris, France., Nicolay N; Vaccine Preventable Diseases and Immunisation, European Centre for Disease Prevention and Control (ECDC), Solna, Sweden., Braeye T; Sciensano, Juliette Wytsmanstraat 14. 1050, Elsene, Belgium., Van Evercooren I; Sciensano, Juliette Wytsmanstraat 14. 1050, Elsene, Belgium., Hansen CH; Department of Infectious Disease Epidemiology and Prevention, Statens Serum Institut, Copenhagen, Denmark., Moustsen-Helms IR; Department of Infectious Disease Epidemiology and Prevention, Statens Serum Institut, Copenhagen, Denmark., Sacco C; Infectious Diseases Department, Istituto Superiore di Sanità, Rome, Italy; European Programme on Intervention Epidemiology Training (EPIET), European Centre for Disease Prevention and Control, Stockholm, Sweden., Mateo-Urdiales A; Infectious Diseases Department, Istituto Superiore di Sanità, Rome, Italy., Castilla J; Instituto de Salud Pública de Navarra - IdiSNA, Pamplona, Spain; CIBER on Epidemiology and Public Health, Spain., Martínez-Baz I; Instituto de Salud Pública de Navarra - IdiSNA, Pamplona, Spain; CIBER on Epidemiology and Public Health, Spain., Machado A; Instituto Nacional de Saúde Doutor Ricardo Jorge, Departamento de Epidemiologia, Lisboa, 1600-609, Portugal., Brito A; Instituto Nacional de Saúde Doutor Ricardo Jorge, Departamento de Epidemiologia, Lisboa, 1600-609, Portugal., Ljung R; Swedish Medical Products Agency, Uppsala, Sweden; Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden., Pihlstrom N; Swedish Medical Products Agency, Uppsala, Sweden; Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden., Mansiaux Y; Epiconcept, Paris, France., Monge S; Department of Communicable Diseases, National Centre of Epidemiology, Institute of Health Carlos III, Madrid, Spain; CIBER on Infectious Diseases, Spain., Bacci S; Vaccine Preventable Diseases and Immunisation, European Centre for Disease Prevention and Control (ECDC), Solna, Sweden., Nunes B; Epiconcept, Paris, France.
Corporate Authors: VEBIS-EHR working group
Source: Vaccine [Vaccine] 2025 Oct 03; Vol. 64, pp. 127752. Date of Electronic Publication: 2025 Sep 19.
Publication Type: Journal Article
Journal Info: Publisher: Elsevier Science Country of Publication: Netherlands NLM ID: 8406899 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-2518 (Electronic) Linking ISSN: 0264410X NLM ISO Abbreviation: Vaccine Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1873-2518
DOI:10.1016/j.vaccine.2025.127752